DIFFERENTIATED THYROID CANCER (DTC)
Clinical trials for DIFFERENTIATED THYROID CANCER (DTC) explained in plain language.
Never miss a new study
Get alerted when new DIFFERENTIATED THYROID CANCER (DTC) trials appear
Sign up with your email to follow new studies for DIFFERENTIATED THYROID CANCER (DTC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Cancer patients to continue promising treatments in major extension trial
Disease control Not yet recruitingThis long-term extension study offers continued access to several cancer drugs—including cabozantinib, atezolizumab, and nivolumab—for up to 5,000 patients who benefited from them in earlier Exelixis-sponsored trials. The study focuses on monitoring safety and ongoing clinical be…
Matched conditions: DIFFERENTIATED THYROID CANCER (DTC)
Phase: PHASE3 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Can a pamphlet ease the anxiety of choosing thyroid cancer treatment?
Symptom relief Not yet recruitingLow-risk thyroid cancer grows very slowly and has a 99% survival rate, but choosing among three treatment options can be stressful. This study gives patients a decision aid pamphlet right after diagnosis, before they see a surgeon. The pamphlet explains the options and lists ques…
Matched conditions: DIFFERENTIATED THYROID CANCER (DTC)
Phase: NA • Sponsor: University of Maryland, Baltimore • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC